Despite the role of CCL2 in recruiting both cytotoxic T cells (CTL) and monocytes to tumor sites [61,62], studies have shown that enhancement of the CCL2/CCR2 axis [63] or inhibition of CCL2 nitration [64] in antitumor therapy significantly promotes T-cell infiltration and exerts antitumor effects. The gene discussed is CCR2; the disease is neoplasm.